Potential role of muscarinic receptors in schizophrenia. (Q48268803)

10 February 2018

title

Potential role of muscarinic receptors in schizophrenia. (English)

1 reference

10 February 2018

main subject

schizophrenia

0 references

author

Michael D. B. Swedberg

11

1 reference

10 February 2018

author name string

F P Bymaster

1

1 reference

10 February 2018

H E Shannon

2

1 reference

10 February 2018

K Rasmussen

3

1 reference

10 February 2018

N W DeLapp

4

1 reference

10 February 2018

J S Ward

5

1 reference

10 February 2018

D O Calligaro

6

1 reference

10 February 2018

C H Mitch

7

1 reference

10 February 2018

C Whitesitt

8

1 reference

10 February 2018

T S Ludvigsen

9

1 reference

10 February 2018

M Sheardown

10

1 reference

10 February 2018

T Rasmussen

12

1 reference

10 February 2018

P H Olesen

13

1 reference

10 February 2018

L Jeppesen

14

1 reference

10 February 2018

P Sauerberg

15

1 reference

10 February 2018

A Fink-Jensen

16

1 reference

10 February 2018

language of work or name

English

0 references

publication date

1 January 1999

1 reference

10 February 2018

published in

Life Sciences

1 reference

10 February 2018

volume

64

1 reference

10 February 2018

issue

6-7

1 reference

10 February 2018

page(s)

527-534

1 reference

10 February 2018

The dopamine hypothesis of schizophrenia: current status, future prospects.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Prospects for pharmacotherapy of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Differential cholinergic innervation within functional subdivisions of the human cerebral cortex: a choline acetyltransferase study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Elevation of acetylcholine levels in striatum of rat brain by LY163502, trans-(-)-5,5a,6,7,8,9a,10-octahydro-6-propylpyrimido less than 4,5-g greater than quinolin-2-amine dihydrochloride, a potent and stereospecific dopamine (D2) agonist.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

The effects of physostigmine in phenothiazine resistant chronic schizophrenic patients: preliminary observations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Antagonistic Effects of Physostigmine and Methylphenidate in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Physostigmine and lithium response in the schizophrenias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Pharmacological Specificity of Conditioned Avoidance Response Inhibition in Rats: Inhibition by Neuroleptics and Correlation to Dopamine Receptor Blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Central cholinergie blockade of the conditioned avoidance response in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Production of climbing behaviour in mice requires both D1 and D2 receptor activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900597-9

10.1016/S0024-3205(98)00597-9

7 January 2021

Identifiers

DOI

1 reference

10 February 2018

PubMed ID

10069519

1 reference

10 February 2018